Identification of functionally variant MDR1 alleles among European Americans and African Americans
By R. Kim, B. Leake, E. Choo, G. Dresser, Samir Kubba, U. Schwarz, A. Taylor, Hong‐Guang Xie, J. McKinsey, Sheng-Wen Zhou and 4 more. Clinical pharmacology and therapy, 2001
1,048 citations recorded by the source corpus.
Subfields: Genetics, Oncology, Pediatrics, Perinatology and Child Health
View Paper: https://www.semanticscholar.org/paper/c87388e23141faaef086df7e9b8c62d73df0998a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Oncology
In Pediatrics, Perinatology and Child Health
Citations in the corpus
- Role of P-Glycoprotein in Pharmacokinetics (2003, background): “Kim et al. [57] showed that individuals harbouring homozygous T-allele mutation tended to have lower plasma AUC 24 of fexofenadine .”
- Xenobiotic, Bile Acid, and Cholesterol Transporters: Function and Regulation (2010, background): “Consistent with enhanced in vitro transport activity, the Ala893Ser ABCB1 (MDR1) variant is associated with reduced plasma fexofenadine concentrations (Table 19) (Kim et al., 2001).”
- Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. (2003, background): “25 We have demonstrated that the C3435T polymorphism in ABCB1 is associated with drug resistance in epilepsy, irrespective of the type of epilepsy or antiepileptic drug used.”
- Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance (2004, background): “Studies from this laboratory demonstrated that a linkage disequilibrium exists between SNPs in exon 26 (C3435T) and exon 21 (G2677T/A), suggesting that the observed functional differences in P-gp, initially attributed to the exon 26 synonymous SNP, may be the result of the associated nonsynonymous p”
- P-glycoprotein: from genomics to mechanism (2003, background): “It occurred in 62% of European Americans, and 13% of African Americans (Kim et al., 2001).”
- Primary Hepatocytes: Current Understanding of the Regulation of Metabolic Enzymes and Transporter Proteins, and Pharmaceutical Practice for the Use of Hepatocytes in Metabolism, Enzyme Induction, Transporter, Clearance, and Hepatotoxicity Studies (2007, background): “Importantly, clinical data have demonstrated the implications of drug transporter polymorphisms for the pharmacokinetics of drugs (Kim et al., 2001; Nishizato et al., 2003).”